177Lu-PSMA新辅助联合立体定向消融放疗治疗寡复发前列腺癌的II期随机研究
LUNAR研究为单中心随机开放标签II期试验,入组92例PSMA PET/CT确认1-5个病灶的寡复发激素敏感前列腺癌患者,1:1随机接受SBRT或两周期177Lu-PNT2002后SBRT。
要点
- 177Lu-PNT2002联合SBRT较单用SBRT显著改善寡复发激素敏感前列腺癌的PFS。
- 联合组中位PFS为17.6个月,单用SBRT组为7.4个月,HR 0.37(95%CI 0.22-0.61)。
- 联合治疗未增加3级及以上毒性,仅见淋巴细胞减少。
核心结论
- 在寡复发激素敏感前列腺癌患者中,SBRT前加用两周期177Lu-PNT2002较单用SBRT显著延长PFS,且未增加毒性。
研究设计与样本
- LUNAR为单中心、随机、开放标签、对照II期试验,在美国加州大学洛杉矶分校开展。
- 入组标准为PSMA PET/CT确认1-5个病灶的寡复发激素敏感前列腺癌,按分期和病灶数分层后1:1随机。
- 共92例患者随机(SBRT组47例,177Lu+SBRT组45例),可评估87例(SBRT组42例,177Lu+SBRT组45例)。
- 联合组接受两周期177Lu-PNT2002(6.8 GBq/周期,间隔2周)后行SBRT;主要终点为PFS(PSMA PET/CT进展、挽救性激素治疗或死亡)。
主要发现
- 唯一3级不良事件为淋巴细胞减少,SBRT组2例(4.8%),联合组3例(6.7%)。
- 研究识别了PFS的预后生物标志物。
关键数值与推荐
- 3级淋巴细胞减少发生率:SBRT组4.8%(2/42),联合组6.7%(3/45)。
临床怎么用
- 对于PSMA PET/CT确认1-5个病灶的寡复发激素敏感前列腺癌,可考虑在SBRT前加用两周期177Lu-PNT2002以延长PFS。
- 联合方案未显著增加3级及以上毒性,淋巴细胞减少为主要3级不良事件。
局限性
- 单中心研究,样本量较小(92例随机),随访时间较短(中位22个月)。
- 开放标签设计可能引入偏倚。
- 需进一步验证预后生物标志物及长期生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy to SBRT would improve outcomes. METHODS: The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959). RESULTS: From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177Lu + SBRT group). Prognostic biomarkers for PFS were identified. CONCLUSION: Compared with SBRT alone, the addition of 177Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.
引用
- Kishan AU, Valle LF, Wilhalme H, et al. 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025. PMID: 41223345. doi:10.1200/JCO-25-01553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。